Table 2.

Summary of tumor characteristics in the cervix and vagina

GenotypeCancer incidence (%)*LIC incidence (%)Tumor multiplicity (tumors/mouse)Tumor burden (area of tumor invasion/mouse; mm2)
NTG (n = 23)8.700.095 × 10−3
E6AP−/− (n = 19)15.800.212 × 10−3
K14E6WT (n = 39)30.817.90.510.39§
K14E6WTE6AP−/− (n = 16)6.300.133 × 10−3**
NTG (n = 7)0000
K14E7WT (n = 22)509.11.80.17
K14E7WTE6AP−/− (n = 7)57.114.3††2.30.38
K14E6WTE7WT (n = 17)82.4415.61.31
K14E6WTE7WTE6AP−/− (n = 6)5003.20.15‡‡

NOTE: Animals represented in the top four lines of the table (up to and including K14E6WT E6AP−/−) were treated with estrogen for 9 mo, whereas the five listed below were treated for 6 mo. All statistical tests were two-sided.

  • *Cancer incidence was defined as the incidence of cancer that occurred in the cervix and the LRT combined.

  • Loss of E6AP resulted in a marginally significant reduction in the formation of LIC in K14E6WTE6AP−/− relative to K14E6WT transgenic mice (P = 0.09).

  • Tumor multiplicity is significantly higher in K14E6WT transgenic mice relative to NTG mice (P < 0.05).

  • §K14E6WT transgenic mice have significantly larger tumors than NTG mice (P < 0.05).

  • Loss of E6AP resulted in a reduction in cancer incidence in K14E6WTE6AP−/− and was significantly different than K14E6WT transgenic mice (P = 0.04).

  • Loss of E6AP results in a reduction in tumor multiplicity in K14E6WTE6AP−/− relative to K14E6WT transgenic mice (P = 0.06).

  • **Loss of E6AP results in a significant reduction in tumor size in K14E6WTE6AP−/− relative to K14E6WT transgenic mice (P < 0.05).

  • ††Loss of E6AP did not result in a reduction in the percentage of LIC in K14E7WTE6AP−/− and was not different than K14E7WT transgenic mice (P > 0.05).

  • ‡‡Loss of E6AP in K14E6WTE7WTE6AP−/− transgenic mice resulted in smaller tumors relative to K14E6WTE7WT transgenic mice (P = 0.07).